Results 181 to 190 of about 23,640 (262)
Longitudinal multi-trajectory phenotypes of severe eosinophilic asthma on type 2 biologics treatment. [PDF]
Pham DD +28 more
europepmc +1 more source
Abstract The landscape of asthma management is undergoing significant transformation. This change is driven by several factors: deeper understanding of asthma pathophysiology, appreciation of the long‐term harm of oral corticosteroids, biological treatments that dramatically improve patient outcomes with asthma remission becoming a realistic goal, and ...
John Politis +4 more
wiley +1 more source
The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma. [PDF]
Rimkunas A +6 more
europepmc +1 more source
Serum Eosinophil‐Derived Neurotoxin (EDN) as a Biomarker for Treatment Response in Atopic Dermatitis
Clinical &Experimental Allergy, EarlyView.
J. I. Olydam +3 more
wiley +1 more source
Tissue Resident Memory Cells: Friend or Foe?
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude +2 more
wiley +1 more source
Consensus from European experts on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: Results from the OverSEA Delphi study. [PDF]
Bachert C +10 more
europepmc +1 more source
Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta +5 more
wiley +1 more source

